Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
 Annual Meeting 2016 - EconoTimes)
SOUTH SAN FRANCISCO, Calif., April 14, 2016 -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that new data from a pharmacokinetic modeling study designed to identify the dose of cerdulatinib for expansion cohorts in a Phase 2 study will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2016, which is taking place from April 16-20 in New Orleans.
Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies. Portola is evaluating cerdulatinib in an ongoing Phase 1/2 study in patients with relapsed/refractory B-cell malignancies who have failed multiple therapies.
The abstract will be made available at www.AACR.org.
Poster Presentation Details
- Abstract Title (#CT144): Preclinical and clinical studies and modeling and simulation to identify Phase 2 dose for cerdulatinib: a dual SYK/JAK inhibitor for the treatment of B-cell malignancies
- Presenting Author: Janet M. Leeds, Ph.D., Senior Director, Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals
- Poster Session Title: Phase I Clinical Trials 2
- Presentation Date and Time: Wednesday, April 20, 7:30 a.m. – 11 a.m. Central Time
- Location: Ernest N. Morial Convention Center, Halls G-J, Poster Section 13
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company is advancing three programs, including betrixaban, an oral, once-daily Factor Xa inhibitor; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions. For more information, visit www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact: Ana Kapor Portola Pharmaceuticals [email protected] Media Contact: Julie Normart W2O Group [email protected]
